Fundz

Fundz Deep Dive

Everything you need to win Melodia Therapeutics AG — in one platform.

Who to reach, what to say, and why now on Melodia Therapeutics AG — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Melodia Therapeutics AG — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A

Jun 29, 2024•almost 2 years ago

Contract Type

agreement

BaselBiotechnologyTherapeuticsresearch

Description

Melodia Therapeutics AG and Alivexis, Inc. have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis' MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential. The agreement includes upfront payment and development and sales milestone payments totaling up to approximately $275 million (JPY 42.7 billion1), with additional royalties on net sales of any marketed product.

Company Information

Company

Melodia Therapeutics AG

Location

Basel, Basel-City, Switzerland

About

Melodia Therapeutics is a Swiss-based biotechnology company focused on developing oral therapies that target neutrophilic inflammation. Its lead candidate, MLD-151, is a novel DPP1 inhibitor designed to suppress pathologic neutrophil protease activity. Melodia aims to translate compelling preclinical data into human proof-of-concept to offer patients superior clinical benefit.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Melodia Therapeutics AG's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.